About | Free Trial

Last Update

2016-05-16T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Nicholas Plotnikoff?

Dr. Nicholas Plotnikoff P.

Non-Voting, Non-Executive Chairman

Immune Therapeutics, Inc.

HQ Phone: (888) 613-8802

Immune Therapeutics, Inc.

37 North Orange Avenue Suite 607

Orlando, Florida 32801

United States

Company Description

Immune Therapeutics is a specialty pharmaceutical company undergoing a wide range of FDA testing of therapeutic protocols preparatory to the manufacture, commercialization, marketing, and distribution of their patented therapies. more

Find other employees at this company (7)

Background Information

Employment History

Professor of Pharmacology
University of Illinois Medical Center

Affiliations

Founder
TNI BioTech Inc

Education



American Board of Toxicology

Ph.D.

China Medical University

Web References (48 Total References)


Dr. Nicholas ...

www.sec.gov [cached]

Dr. Nicholas Plotnikoff

...
Dr. Nicholas Plotnikoff - Dr. Plotnikoff has served as our non-voting, Non-Executive Chairman of the Board since March 2012. Dr. Plotnikoff has a Ph.D. in Pharmacology and over 20 years' experience in the pharmaceutical industry working in Pharmacology, Toxicology, and Clinical Research. Prior to joining our Board, Dr. Plotnikoff was a Professor of Pharmacology at the University of Illinois Medical Center in Chicago from December 1987 until his retirement in May 2008. Dr. Plotnikoff formed TNI Pharmaceutical, Inc. in 1987, which became a public company in 1991. Dr. Plotnikoff served as its Chief Executive Officer and President for 20 years where he helped develop the immunological effects of MENK. He successfully managed the project teams that developed the new drug applications for Traxene (a Valium-like tranquilizer) and Cylert (a non-amphetamine psychostimulant). Dr. Plotnikoff was responsible for the Phase I and Phase II trials for MENK in HIV/AIDS. In basic research, he was the first to identify the central nervous system effects of hypothalamic releasing factors (brain hormones), resulting in clinical development for treatment of depression and Parkinson's disease. Dr. Plotnikoff has co-authored 25 publications with Dr. Andrew Schally, covering basic research in the field of depression and Parkinson's disease.
...
Dr. Plotnikoff was issued a number of international patents for the use of MENK in HIV/AIDS and cancer, which we acquired in 2012.
...
From 2000 to present, Dr. Shan has worked both in the United States and China on the clinical trials with Dr. Nicholas Plotnikoff involving new immunotherapies for the treatment of cancer.


PREVENTING AIDS WITH LDN IN MALI, AFRICA

www.ldnafricaaids.org [cached]

Dr. Nicholas Plotnikoff, Chairman of TNI BioTech, recently announced that his company has acquired all of Dr. Bernard Bihari's use-patents for low dose naltrexone.


LDN: The Latest News

www.lowdosenaltrexone.org [cached]

Dr. Nicholas Plotnikoff, Chairman of TNI BioTech, recently announced that his company has acquired all of Dr. Bernard Bihari's use-patents for low dose naltrexone.

...
Dr. Plotnikoff, quoted on the TNI BioTech website, said:
...
Dr. Plotnikoff, Emeritus Professor of Pharmacology and Psycho­neuro­immuno­logy, College of Pharmacy and College of Medicine, at the University of Illinois in Chicago, holds a PhD in Pharmacology. Prior to TNI, Dr. Plotnikoff helped direct research for Abbott Labs.
...
Following welcoming remarks from Jeffrey Abrams, MD, Chief of the Clinical Investigations Branch of the NCI, speakers included David Gluck, MD (Introductory Overview); Jill Smith, MD (Clinical Experience with LDN in Crohn's Disease; Opioid Growth Factor in Pancreatic Cancer); John Hong, PhD (Anti-Inflammatory and Neuroprotective Effects of Naltrexone and Its Analogs); Nicholas Plotnikoff, PhD (Overview of Metenkephalin Actions in HIV Infections); Burton M. Berkson, MD, PhD (Personal Experiences with LDN for Various Cancers); Maira Gironi, MD, PhD and Filippo M. Boneschi, MD, PhD (Ongoing Pilot Study of LDN in MS: Preliminary Findings).
...
Invitees thus far include I. Zagon, PhD; Jill P. Smith, MD; John Hong, PhD; and Nicholas Plotnikoff, PhD; as well as physician practitioners with experiences in LDN treatment.


LDN: The Latest News

www.ldninfo.org [cached]

Dr. Nicholas Plotnikoff, Chairman of TNI BioTech, recently announced that his company has acquired all of Dr. Bernard Bihari's use-patents for low dose naltrexone.

...
Dr. Plotnikoff, quoted on the TNI BioTech website, said:
...
Dr. Plotnikoff, Emeritus Professor of Pharmacology and Psycho­neuro­immuno­logy, College of Pharmacy and College of Medicine, at the University of Illinois in Chicago, holds a PhD in Pharmacology. Prior to TNI, Dr. Plotnikoff helped direct research for Abbott Labs.
...
Following welcoming remarks from Jeffrey Abrams, MD, Chief of the Clinical Investigations Branch of the NCI, speakers included David Gluck, MD (Introductory Overview); Jill Smith, MD (Clinical Experience with LDN in Crohn's Disease; Opioid Growth Factor in Pancreatic Cancer); John Hong, PhD (Anti-Inflammatory and Neuroprotective Effects of Naltrexone and Its Analogs); Nicholas Plotnikoff, PhD (Overview of Metenkephalin Actions in HIV Infections); Burton M. Berkson, MD, PhD (Personal Experiences with LDN for Various Cancers); Maira Gironi, MD, PhD and Filippo M. Boneschi, MD, PhD (Ongoing Pilot Study of LDN in MS: Preliminary Findings).
...
Invitees thus far include I. Zagon, PhD; Jill P. Smith, MD; John Hong, PhD; and Nicholas Plotnikoff, PhD; as well as physician practitioners with experiences in LDN treatment.


Board of Directors

www.tnibiotech.com [cached]

Dr. Nicholas Plotnikoff, Non-Executive Chairman ?

...
Dr. Plotnikoff has a Ph.D. in Pharmacology, with over 20 years in the pharmaceutical industry, working in Pharmacology, Toxicology, and Clinical Research. Dr. Plotnikoff was a Professor of Pharmacology at the University of Illinois Medical Center in Chicago. Dr. Plotnikoff played a pioneering role in investigations of the immunological effects of MENK. He also successfully managed the project teams that developed the NDAs on Traxene (Valium-like tranquilizer) and Cylert (non-amphetamine psychostimulant).
In basic research he was the first to identify the central nervous system effects of hypothalamic releasing factors (brain hormones), resulting in their clinical development for treatment of depression and Parkinson's disease. Dr. Plotnikoff co-authored 25 publications with Dr. Andrew Schally covering basic research in the field of depression and Parkinson's disease.
...
Dr. Plotnikoff held a number of international patents for the use of MENK in HIV/AIDS and cancer.

Similar Profiles

Other People with this Name

Other people with the name Plotnikoff

Ronald Plotnikoff
University of Newcastle

Terryl Plotnikoff
Canadian Mattress Recycling Inc

Jill Plotnikoff
York House School

Gerry Plotnikoff
Selkirk College

Mark Plotnikoff
Center For Healthy

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory